Tradestie Institutional Equity Comparison Engine
ACRS vs ATYR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ATYR Overall Edge
ATYR Captures Institutional Edge (3โ0 Pillars ยท 3โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to aTyr Pharma, Inc. Common Stock (ATYR) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ACRS trades at N/M Forward P/E with -1412.4% operating margin (-55.1% YoY revenue) versus ATYR at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ACRS sits in BREAKDOWN (1st %ile IV; Dealer Gamma Walls on Pro) against ATYR sits in UNCLASSIFIED (36th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ACRS N/M vs ATYR N/M Fwd P/E
Growth & Margin Winner
ATYR
Op Margin -1412.4% vs 0.0% ยท YoY -55.1% vs +0.0%
Momentum & Technical Winner
ATYR
1Y +32.7% vs +541.4% ยท 52W Pos 25% vs 60%
Options & Structure Winner
ATYR
BREAKDOWN (1st %ile IV) vs UNCLASSIFIED (36th %ile IV)
ACRS
NASDAQ
Aclaris Therapeutics, Inc.
Pharmaceutical Preparations
$3.35
-7.21% 1D
Market Cap
$621.8M
1M Return
-3.88%
1Y Return
+32.74%
Forward P/E
N/M
Unified AI Score
44.7 / 100
HOLD
Tech 41.0
Fund 54.0
Flow 64.0
Mom 70.0
ATYR
NASDAQ
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.83
-7.82% 1D
Market Cap
$15.6M
1M Return
+2713.05%
1Y Return
+541.43%
Forward P/E
N/M
Unified AI Score
34.3 / 100
SELL
Tech 50.0
Fund 36.0
Flow 69.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ACRS +32.74%
ATYR +541.43%
Spread: +508.69 pp (ATYR Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ACRS Revenue | ATYR Revenue | ACRS Op. Margin | ATYR Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $10M | N/A | -1378.3% | N/A | ACRS |
| FY2019 | $0M | $0M | -2627.3% | -5445.0% | ACRS |
| FY2020 | $10M | $10M | -785.4% | -152.2% | ATYR |
| FY2021 | $10M | N/A | -1327.1% | N/A | ACRS |
| FY2022 | $30M | $10M | -302.0% | -446.8% | ACRS |
| FY2023 | $30M | $0M | -311.6% | -15557.8% | ACRS |
| FY2024 | $20M | $0M | -758.2% | -28899.6% | ACRS |
| FY2025 | $10M | $0M | -975.9% | -40856.3% | ACRS |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ACRS | ATYR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $621.8M | $15.6M | Larger Scale | ACRS |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -55.1% | +0.0% | Higher Growth | ATYR |
| Operating Margin (TTM) Profitability | -1412.4% | 0.0% | Higher Margin | ATYR |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -55.5% | -93.7% | Higher ROE | ACRS |
| 52-Week Range Position Momentum | 25% ($2โ$7) | 60% ($0โ$8) | Stronger Trend | ATYR |
| Beta / 30D Volatility Risk Regime | 1.56ฮฒ ยท 74% Vol | -9.57ฮฒ ยท 13806% Vol | Lower Realized Risk | ACRS |
| Unified Institutional Score Composite Signal | 44.7 / 100 (HOLD) | 34.3 / 100 (SELL) | Higher Composite | ACRS |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ACRS vs ATYR Buy Guide
ACRS
BREAKDOWN
130d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
1st %ile
IV Regime
Compressed (<25th %ile)
ATYR
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
36th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ACRS nor ATYR registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.